What is claimed is:

1. A non-aqueous high concentration protein formulation, comprising:

a. at least about 200 mg/mL of a therapeutic protein as a micronized solid protein formulation,

b. a hydrophobic agent comprising glyceryl tricaprylate/tricaprate, and

c. a viscosity-reducing agent selected from the group consisting of ethanol, benzyl alcohol, ethyl acetate, N-Methyl-2-pyrrolidone, or combinations thereof,

wherein the formulation has at least 25% v/v of the viscosity-reducing agent and an injection glide force of less than about 30 Newton.

2. The non-aqueous high concentration protein formulation of claim 1, wherein the micronized solid protein formulation is produced by spray drying.

3. The non-aqueous high concentration protein formulation of claim 1, wherein said micronized solid protein formulation has a solubility of less than about 1 mg in 10,000 mL in the hydrophobic agent and the viscosity-reducing agent.

4. The non-aqueous high concentration protein formulation of claim 1, wherein said micronized solid protein formulation is in the form of a powder.

5. The non-aqueous high concentration protein formulation of claim 4, wherein said powder is formulated using trileucine.

6. The non-aqueous high concentration protein formulation of claim 4, wherein the concentration of said powder is between about 200 mg/mL to about 500 mg/mL.

7. The non-aqueous high concentration protein formulation of claim 4, wherein the weight ratio (w/w) of said powder to the non-aqueous high concentration protein formulation is between about 0.250 and 0.700.

8. The non-aqueous high concentration protein formulation of claim 4, wherein said powder comprises the therapeutic protein, a carbohydrate, an amino acid, or a non-ionic surfactant.

9. The non-aqueous high concentration protein formulation of claim 8, wherein the carbohydrate is sucrose, mannitol, or trehalose.

10. The non-aqueous high concentration protein formulation of claim 8, wherein the amino acid is histidine or proline.

11. The non-aqueous high concentration protein formulation of claim 8, wherein the non-ionic surfactant is a polysorbate.

12. The non-aqueous high concentration protein formulation of claim 8, wherein the concentration of the protein is at least about 70%.

13. The non-aqueous high concentration protein formulation of claim 1, wherein said therapeutic protein is a monoclonal antibody.

14. A non-aqueous high concentration protein formulation, comprising:

at least about 200 mg/mL of a therapeutic protein as a micronized solid protein formulation,

glyceryl tricaprylate/tricaprate, and

benzyl alcohol,

wherein the formulation has at least 25% v/v of the viscosity-reducing agent and an injection glide force of less than about 30 Newton.

15. A non-aqueous high concentration protein formulation, comprising:

a. at least about 200 mg/mL of a therapeutic protein as a micronized solid protein formulation,

b. a hydrophobic agent comprising glyceryl tricaprylate/tricaprate, and

c. a viscosity-reducing agent selected from the group consisting of ethanol, benzyl alcohol, benzyl benzoate, ethyl acetate, N-Methyl-2-pyrrolidone, or combinations thereof,

wherein the formulation has at least 25% v/v of the viscosity-reducing agent wherein the non-aqueous high concentration protein formulation has an injection glide force of less than about 50 Newton (N).